- Home
- KZIA vs POAI Comparison
KZIA vs POAI Comparison
Compare KZIA & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- POAI
- Stock Information
- Founded
- KZIA 1994
- POAI 2002
- Country
- KZIA Australia
- POAI United States
- Employees
- KZIA N/A
- POAI N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- POAI Industrial Specialties
- Sector
- KZIA Health Care
- POAI Health Care
- Exchange
- KZIA Nasdaq
- POAI Nasdaq
- Market Cap
- KZIA 9.0M
- POAI 7.8M
- IPO Year
- KZIA 1999
- POAI N/A
- Fundamental
- Price
- KZIA $6.71
- POAI $9.26
- Analyst Decision
- KZIA Strong Buy
- POAI Hold
- Analyst Count
- KZIA 3
- POAI 1
- Target Price
- KZIA $16.00
- POAI N/A
- AVG Volume (30 Days)
- KZIA 188.3K
- POAI 252.6K
- Earning Date
- KZIA 11-14-2025
- POAI 11-11-2025
- Dividend Yield
- KZIA N/A
- POAI N/A
- EPS Growth
- KZIA N/A
- POAI N/A
- EPS
- KZIA N/A
- POAI N/A
- Revenue
- KZIA $1,549,158.00
- POAI $1,664,696.00
- Revenue This Year
- KZIA N/A
- POAI $486.27
- Revenue Next Year
- KZIA $49.25
- POAI $65.50
- P/E Ratio
- KZIA N/A
- POAI N/A
- Revenue Growth
- KZIA 248983.08
- POAI 71.65
- 52 Week Low
- KZIA $2.86
- POAI $9.14
- 52 Week High
- KZIA $39.05
- POAI $45.90
- Technical
- Relative Strength Index (RSI)
- KZIA 41.14
- POAI 49.87
- Support Level
- KZIA $6.82
- POAI $9.14
- Resistance Level
- KZIA $7.39
- POAI $14.65
- Average True Range (ATR)
- KZIA 0.45
- POAI 1.05
- MACD
- KZIA 0.02
- POAI -0.92
- Stochastic Oscillator
- KZIA 28.33
- POAI 2.00
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.